Efgartigimod for primary immune thrombocytopenia: the ADVANCE IV trial – Authors' reply

Additionally, although we recognise the potential ability of neonatal Fc receptor inhibitors to modulate fetal and neonatal alloimmune disease resulting from parental red cell or platelet incompatibility, formal and careful studies are needed to evaluate the safety and efficacy of this approach. Ide...

Full description

Saved in:
Bibliographic Details
Published in:The Lancet (British edition) 2024-08, Vol.404 (10451), p.434-434
Main Authors: Al-Samkari, Hanny, B Bussel, James, Miyakawa, Yoshi, Broome, Catherine M
Format: Article
Language:English
Subjects:
Blood
Blood platelets
Children
Clinical trials
Fc receptors
Fetuses
Humans
Idiopathic thrombocytopenic purpura
Incompatibility
Laboratories
Neonates
Platelets
Purpura, Thrombocytopenic, Idiopathic - drug therapy
Quality of life
Randomized Controlled Trials as Topic
Research funding
Thrombocytopenia
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Additionally, although we recognise the potential ability of neonatal Fc receptor inhibitors to modulate fetal and neonatal alloimmune disease resulting from parental red cell or platelet incompatibility, formal and careful studies are needed to evaluate the safety and efficacy of this approach. Ideally, advances in testing will reliably allow additional such evaluations in the future to better evaluate the mechanism of treatment effect and potentially allow for the establishment of laboratory profiles that predict response. JBB reports honoraria from Novartis, Sobi, Alpine, UCB, argenx, Janssen, and RallyBio; and unpaid leadership roles in a board, society, or advocacy group with Platelet Disorder Society of America, Children's Cancer and Blood Foundation, and Foundation for Women and Girls with Blood Disorders.
ISSN:0140-6736
1474-547X
1474-547X
DOI:10.1016/S0140-6736(24)01263-7